TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16845899

Group type: EXPERIMENTAL
Intervention: Bayesian modelling strategy for multivariate outcomes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Informative priors for intracluster correlation coefficients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified existing approach for multivariate outcomes
Number of subjects: 0
Study: 15053497

Group type: EXPERIMENTAL
Intervention: Individualized treatment program including fines, community service, monetary restitution, written essays, anti-shoplifting videos, apology letters, and individual and/or family counseling
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Individualized treatment program
Number of subjects: 286

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 286
Study: 10925339

Group type: EXPERIMENTAL
Intervention: 10 mg/day atorvastatin
Number of subjects: 22
Study: 8882238

Group type: EXPERIMENTAL
Intervention: Midazolam (5 mg.70 kg‐1 bolus at induction followed by 1 mg.70 kg‐1.h‐1 continuous infusion for 48 h)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 1812099

Group type: EXPERIMENTAL
Intervention: Bajra
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Barley
Number of subjects: 32

Group type: COMPARATOR
Intervention: Maize
Number of subjects: 32
Study: 6613138

Group type: COMPARATOR
Intervention: Supportive care (45 cases)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: High-dose irradiation of 40 to 66 Gy (59 cases)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: COMP protocol (CCNU, procarbazine, vincristine, methotrexate, prednisone in 15 day cycles - 42 cases)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Simultaneous irradiation and COMP chemotherapy (80 cases including 30 survivors)
Number of subjects: 226
Study: 30813934

Group type: EXPERIMENTAL
Intervention: Intramuscular 17-alpha hydroxprogesterone caproate (17P)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study: 28365852

Group type: EXPERIMENTAL
Intervention: Anterior glenohumeral joint approach
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Posterior glenohumeral joint approach
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Rotator interval approach
Number of subjects: 98

Group type: COMPARATOR
Intervention: Residents (1st or 2nd year)
Number of subjects: 98
Study: 26771622

Group type: EXPERIMENTAL
Intervention: Post-incarceration (3 weeks after release)
Number of subjects: 208
Study: 21822678

Group type: EXPERIMENTAL
Intervention: Habitual diet plus additional food supplement (SUP, n=15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Habitual diet (CON, n=15)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SUP
Number of subjects: 30

Group type: COMPARATOR
Intervention: CON
Number of subjects: 30
Study: 19570929

Group type: EXPERIMENTAL
Intervention: Computerized cognitive training
Number of subjects: 55

Group type: COMPARATOR
Intervention: Computer games control condition
Number of subjects: 55
Study: 17686833

Group type: EXPERIMENTAL
Intervention: Hypocaloric, low-fat diet (n = 20)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Weight maintenance diet (n = 15)
Number of subjects: 35
Study: 15339761

Group type: EXPERIMENTAL
Intervention: Duloxetine 80 mg/d for 4 weeks, escalated to 120 mg/d for 4 weeks
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 11498677

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0
Study: 9849386

Group type: EXPERIMENTAL
Intervention: Barium-impregnated silicone rubber spheres (2 mm in diameter)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PMMA markers (3.0 mm in diameter)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tantalum marker (2.5 mm in diameter)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ring-shaped markers in PMMA (2.6 mm and 3.0 mm in diameter)
Number of subjects: 0
Study: 9138335

Group type: EXPERIMENTAL
Intervention: Etoposide and mitoxantrone
Number of subjects: 25

Group type: COMPARATOR
Intervention: Citarabine (standard, intermediate or high doses) combined with daunomicin or mitoxantrone
Number of subjects: 25
Study: 2476604

Group type: EXPERIMENTAL
Intervention: Potassium supplements (64 mmol daily)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (made of starch with coating)
Number of subjects: 48
Study: 1259099

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 20

Group type: COMPARATOR
Intervention: Meperidine
Number of subjects: 20
Study: 31300874

Group type: EXPERIMENTAL
Intervention: Mouth rinsing
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Mouth drying
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 87
Study: 29961888

Group type: EXPERIMENTAL
Intervention: Immediate one-time nephrological consultation after randomization, implementing KDIGO 2012 recommendations on AKI.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (non-intervention group)
Number of subjects: 100
Study: 27330154

Group type: EXPERIMENTAL
Intervention: Intact hydrocodone ER 45-mg tablet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Finely crushed hydrocodone ER 45-mg tablet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrocodone IR 45-mg powder
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24816760

Group type: EXPERIMENTAL
Intervention: Intra-articular injection of tranexamic acid (TXA) 500 mg in 20 mL of normal saline solution, applied into the joint for 5 min at the end of surgery.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group received an equivalent volume of normal saline solution, applied into the joint for 5 min at the end of surgery.
Number of subjects: 80
Study: 24099796

Group type: EXPERIMENTAL
Intervention: AJ-5 (binuclear palladacycle complex)
Number of subjects: 2
Study: 21592944

Group type: EXPERIMENTAL
Intervention: Observers who could see their haptic explorations of the square
Number of subjects: 40

Group type: COMPARATOR
Intervention: Observers who could not see their haptic explorations of the square
Number of subjects: 40
Study: 19736249

Group type: EXPERIMENTAL
Intervention: Psychiatric examination including diagnostics with Present State Examination and feedback regarding treatment and rehabilitation; 329 (78.3%) participated in the intervention.
Number of subjects: 420

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 420
Study: 16893434

Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg-simvastatin 20 mg
Number of subjects: 153

Group type: COMPARATOR
Intervention: placebo-simvastatin 20 mg
Number of subjects: 153
Study: 15336577

Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin lispro
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous regular insulin
Number of subjects: 40
Study: 10950401

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Combination therapy (amlodipine 5 mg and doxazosin 2 mg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Monotherapy with doxazosin 4 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Monotherapy with amlodipine 10 mg
Number of subjects: 75
Study: 9305715

Group type: EXPERIMENTAL
Intervention: Carboplatin plus amifostine (500 mg/m2 carboplatin + 2 doses of 910 mg/m2 amifostine)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Carboplatin alone (500 mg/m2)
Number of subjects: 55
Study: 8422661

Group type: EXPERIMENTAL
Intervention: Selegiline 5 mg daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Selegiline 10 mg daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Selegiline 0 mg daily (placebo)
Number of subjects: 16
Study: 3537783

Group type: EXPERIMENTAL
Intervention: Intravenous edrophonium (Tensilon)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31690219

Group type: EXPERIMENTAL
Intervention: Rice crackers made from ss3a/be2b mutant rice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cooked rice made from ss3a/be2b mutant rice
Number of subjects: 0
Study: 29582447

Group type: EXPERIMENTAL
Intervention: Sleep study-guided multidisciplinary therapy (SGMT) including overnight sleep study, continuous positive airway pressure, and behavioral therapy for OSA.
Number of subjects: 180

Group type: COMPARATOR
Intervention: Standard therapy for acute coronary syndrome (ACS).
Number of subjects: 180
Study: 27341554

Group type: EXPERIMENTAL
Intervention: Prosthesis users
Number of subjects: 21

Group type: COMPARATOR
Intervention: Intact individuals
Number of subjects: 21
Study: 23880585

Group type: EXPERIMENTAL
Intervention: Nurse-led follow-up at home
Number of subjects: 138

Group type: COMPARATOR
Intervention: Conventional medical follow-up in the outpatient clinic
Number of subjects: 138
Study: 22388001

Group type: EXPERIMENTAL
Intervention: Nebivolol and hydrochlorothiazide (HCTZ)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Nebivolol (10 mg and 20 mg daily)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Nebivolol posttreatment
Number of subjects: 42
Study: 20478471

Group type: EXPERIMENTAL
Intervention: Triple antibiotic mixture (ciprofloxacin, metronidazole, minocycline)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Minocycline (component of the triple antibiotic paste)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Dentin bonding agent
Number of subjects: 1
Study: 18521830

Group type: EXPERIMENTAL
Intervention: Gastrectomy due to incomplete ER and local recurrence after ER
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Gastrectomy specimens with submucosal invasion without margin involvement
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Gastrectomy specimens with margin involvement
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Patients with local recurrence
Number of subjects: 86
Study: 15939717

Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy with 5-Fluorouracil (5-FU) and cisplatin
Number of subjects: 260

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 260
Study: 11820861

Group type: EXPERIMENTAL
Intervention: Wine drinkers
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Spirits drinkers
Number of subjects: 3

Group type: COMPARATOR
Intervention: Teetotalers (Control)
Number of subjects: 3
Study: 10403867

Group type: EXPERIMENTAL
Intervention: Reinforced laryngeal mask airway
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard laryngeal mask airway
Number of subjects: 120

Group type: COMPARATOR
Intervention: Nasal mask
Number of subjects: 120
Study: 7751410

Group type: EXPERIMENTAL
Intervention: Linopirdine (DuP 996) 0.5 to 55 mg in young subjects; 20 to 45 mg in elderly subjects
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 2148280

Group type: EXPERIMENTAL
Intervention: Low-dose enoximone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High-dose enoximone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 359109

Group type: EXPERIMENTAL
Intervention: Butorphanol 1 mg and 2 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Meperidine 40 mg and 80 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Butorphanol
Number of subjects: 80

Group type: COMPARATOR
Intervention: Meperidine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Butorphanol and Meperidine
Number of subjects: 80
Study: 31222759

Group type: EXPERIMENTAL
Intervention: Metabolite-guided treatment approach
Number of subjects: 0
Study: 31223148

Group type: EXPERIMENTAL
Intervention: 90-minute workshop (Group B)
Number of subjects: 183

Group type: COMPARATOR
Intervention: 30-minute lecture (Group A)
Number of subjects: 183

Group type: COMPARATOR
Intervention: No training (Group C)
Number of subjects: 183
Study: 27794631

Group type: EXPERIMENTAL
Intervention: Balance Training (BT)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Lumbar Stabilization (LS)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Task-Oriented Training (TT)
Number of subjects: 42
Study: 26069973

Group type: EXPERIMENTAL
Intervention: Wet cupping therapy (6 sessions within 2 weeks at two bladder meridian acupuncture points)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 80
Study: 23791771

Group type: EXPERIMENTAL
Intervention: Desensitising toothpaste (DT)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Professionally applied dentine bonding agent (DA)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Non-desensitising toothpaste (NDT)
Number of subjects: 75
Study: 21680999

Group type: EXPERIMENTAL
Intervention: Remoxy 5 mg twice daily (10 mg total daily oxycodone dose) for opioid-naïve patients; equivalent dose for opioid-experienced patients based on previous opioid daily dose.
Number of subjects: 823
Study: 19265726

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (concentrated amino acid drink with no tryptophan)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 27
Study: 16458545

Group type: EXPERIMENTAL
Intervention: Prednisone (60 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 14713399

Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclooxygenase-2 selective agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Western Ontario and McMaster Osteoarthritis Index
Number of subjects: 0
Study: 11553420

Group type: EXPERIMENTAL
Intervention: Experimental group received usual care plus individual and group sessions with an asthma nurse.
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group received usual care only.
Number of subjects: 112
Study: 9373758

Group type: EXPERIMENTAL
Intervention: 937 IU vitamin E (d1-alpha-tocopherol acetate)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 432 IU vitamin E (d1-alpha-tocopherol acetate)
Number of subjects: 16
Study: 7516450

Group type: EXPERIMENTAL
Intervention: CAV/PE (cyclophosphamide, doxorubicin, vincristine alternating with cisplatin and etoposide)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: PE (cisplatin and etoposide)
Number of subjects: 351

Group type: COMPARATOR
Intervention: CAV (cyclophosphamide, doxorubicin, vincristine)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: CODE plus G‐CSF (cyclophosphamide, Oncovin, doxorubicin, etoposide with granulocyte-colony stimulating factor)
Number of subjects: 351

Group type: COMPARATOR
Intervention: CODE alone (cyclophosphamide, Oncovin, doxorubicin, etoposide)
Number of subjects: 351
Study: 2887173

Group type: EXPERIMENTAL
Intervention: 2 mg WAL 801 CL
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 6 mg WAL 801 CL
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 18 mg WAL 801 CL
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 2 mg ketotifen
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 29614659

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) levels measured by LAPAQ and activity monitor
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Exercise capacity measured against population normative data
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness
Number of subjects: 121
Study: 27635789

Group type: EXPERIMENTAL
Intervention: Low-dose CT (120 kVp, 45 mAs)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Standard dose CT (120 kVp, 100 mAs)
Number of subjects: 134
Study: 24628076

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 25 mcg
Number of subjects: 43

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 43
Study: 24431884

Group type: EXPERIMENTAL
Intervention: Insulin syringe
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard 3mL syringe
Number of subjects: 40
Study: 21353107

Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg/d or Naproxen 250 mg BID for 8 weeks
Number of subjects: 4101

Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg/d or Naproxen 250 mg BID for 6 months
Number of subjects: 4101

Group type: EXPERIMENTAL
Intervention: Mean postbaseline sUA concentration <6.0 mg/dL
Number of subjects: 4101

Group type: EXPERIMENTAL
Intervention: Prophylaxis duration
Number of subjects: 4101
Study: 18275573

Group type: EXPERIMENTAL
Intervention: Progesterone suppository (400 mg) daily until delivery
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 70
Study: 16187992

Group type: EXPERIMENTAL
Intervention: Clear corneal phacoemulsification and foldable intraocular lens implantation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (filtering surgery without cataract extraction)
Number of subjects: 30
Study: 14969070

Group type: EXPERIMENTAL
Intervention: Early DMARD group (hydroxychloroquine, intramuscular gold, oral methotrexate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pyramid strategy group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MTX or iAU as the first DMARD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: iAU therapy
Number of subjects: 0
Study: 10382188

Group type: EXPERIMENTAL
Intervention: Liquid nutritional supplement between meals and at bedtime
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no nutritional supplement)
Number of subjects: 40
Study: 8694698

Group type: EXPERIMENTAL
Intervention: pyruvate-based peritoneal dialysis solution (pH 5.2)
Number of subjects: 6

Group type: COMPARATOR
Intervention: lactate-based peritoneal dialysis solution (control)
Number of subjects: 6
Study: 1702144

Group type: COMPARATOR
Intervention: ProMACE-MOPP
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: ProMACE-CytaBOM
Number of subjects: 193
Study: 6341639

Group type: EXPERIMENTAL
Intervention: Rhesus diploid‐cell‐strain rabies vaccine (RDRV)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Commercial high‐titer rabies immune globulin, 20 IU/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rhesus diploid‐cell‐strain rabies vaccine (RDRV) without prior rabies immune globulin
Number of subjects: 60
Study: 31062389

Group type: EXPERIMENTAL
Intervention: B2M mutant tumours (39 of 121, 32%)
Number of subjects: 121

Group type: COMPARATOR
Intervention: B2M wild-type tumours (77 total, 14 recurred)
Number of subjects: 121

Group type: COMPARATOR
Intervention: pMMR CRCs (108 total, 3 with deleterious B2M mutations)
Number of subjects: 121
Study: 28788782

Group type: EXPERIMENTAL
Intervention: Quantum-noise randomized cipher (QNRC) system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: QNRC combined with proper channel codes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secrecy of running key
Number of subjects: 0
Study: 25493397

Group type: EXPERIMENTAL
Intervention: AZD6280 10 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: AZD6280 40 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Lorazepam 2 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: AZD6280
Number of subjects: 16
Study: 23689789

Group type: EXPERIMENTAL
Intervention: Self-initiated patient-directed music (PDM) (n = 126)
Number of subjects: 373

Group type: COMPARATOR
Intervention: Usual care (n = 125)
Number of subjects: 373

Group type: COMPARATOR
Intervention: Noise-canceling headphones (NCH) (n = 122)
Number of subjects: 373
Study: 21309709

Group type: EXPERIMENTAL
Intervention: Derris scandens Benth extracts 800 mg/day
Number of subjects: 107

Group type: COMPARATOR
Intervention: Naproxen 500 mg/day
Number of subjects: 107
Study: 19930626

Group type: EXPERIMENTAL
Intervention: Usual care plus point of care prothrombin time testing
Number of subjects: 220

Group type: COMPARATOR
Intervention: Usual care alone without point of care testing
Number of subjects: 220
Study: 16500386

Group type: COMPARATOR
Intervention: Endoscopic sclerotherapy (ES)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: EUS-guided sclerotherapy of collateral vessels (EUS-ES)
Number of subjects: 50
Study: 15476993

Group type: EXPERIMENTAL
Intervention: Disease management program including an educational booklet, an initial 1-hour educational session, and scheduled supportive phone calls over 6 weeks.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Disease management program
Number of subjects: 25
Study: 11597664

Group type: EXPERIMENTAL
Intervention: Bosentan (62.5mg taken twice daily for 4 weeks then 125 mg twice daily)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 32
Study: 9408514

Group type: COMPARATOR
Intervention: Gentamicin 7 mg/kg i.v. once daily by itself
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Gentamicin with piperacillin 4 g and tazobactam 0.5 g every six hours i.v.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Gentamicin with piperacillin 4 g and tazobactam 0.5 g every eight hours i.v.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Gentamicin with piperacillin 8 g and tazobactam 1 g by continuous i.v. infusion over 24 hours
Number of subjects: 10
Study: 7961338

Group type: EXPERIMENTAL
Intervention: Fluoxetine at a dose of 0.6 mg/kg/day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 3328992

Group type: EXPERIMENTAL
Intervention: Anxiety Management (self-help treatment including procedures for managing somatic and cognitive symptoms, avoidance, and low self-confidence)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list group (control)
Number of subjects: 0
Study: 29369074

Group type: EXPERIMENTAL
Intervention: tDCS with ECT
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham tDCS with ECT
Number of subjects: 16
Study: 28057390

Group type: EXPERIMENTAL
Intervention: Lornoxicam 16mg administered 60 minutes before surgery
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Lornoxicam 16mg administered 60 minutes after surgery
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo administered 60 minutes before surgery
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo administered 60 minutes after surgery
Number of subjects: 90
Study: 26572860

Group type: EXPERIMENTAL
Intervention: Very Early Supported Discharge (VESD) with home rehabilitation intervention from a coordinated team
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Very Early Supported Discharge (VESD)
Number of subjects: 10
Study: 23143621

Group type: EXPERIMENTAL
Intervention: 150 mg thalidomide once/day
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: 1 g sulfasalazine, twice/day
Number of subjects: 111

Group type: COMPARATOR
Intervention: NSAIDs for maintenance treatment
Number of subjects: 111